Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Гинкго билоба: итоги полувекового опыта применения Полимодальность эффектов гинкго билоба: экспериментальные и клинические исследования
Гинкго билоба: итоги полувекового опыта применения Полимодальность эффектов гинкго билоба: экспериментальные и клинические исследования
Е.А.Катунина. Гинкго билоба: итоги полувекового опыта применения Полимодальность эффектов гинкго билоба: экспериментальные и клинические исследования. Consilium Medicum. Неврология (Прил.). 2013; 2: 53-57.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Giurgea C. The «nootropic» approach to thepharmacology of the intergrative activity of the brain. Cond Reflex 1973; 8: 108–15.
2. Eckert A, Keil U et al. Effects of Ginkgo biloba extract on mitochondrial function and oxidative stress. Pharmacopsych 2003; 36 (1): S15–S23.
3. Mairs I, Marocci L et al. Peroxyl radical scavenging activity of Ginkgo biloba Extract EG 761. Biochem Pharmacol 1995; 49: 1649–55.
4. Noda Y, Anzai K et al. Hydroxyl and superoxide anion radical scavenging activities of natural source antioxidants using the computerized JES-FR30 ESR spectrometer system. Biochem Mol Biol Int 1997; 42: 35–44.
5. Bridi R, Crossetti FP et al. The antioxidant activity of extract Ginkgo biloba EGb761 in rats. Phytother Res 2001; 15: 449–51.
6. Abdel-Kader R, Hauptmann S, Keil U et al. Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761H). Pharmacol Res 2007; 56: 493–502.
7. Sastre J, Lloret A et al. Ginkgo biloba extract EGb 761 protects against mitochondrial aging in rat brain and in the liver. Cell Mol Biol 2002; 48: 685–92.
8. Auguet M, DeFeudis FV, Clostre F, Deghenghi R. Effects of an extract of Ginkgo biloba on rabbit isolated aorta. Gen Pharmacol 1982; 13 (3): 225–30.
9. Kehr J, Yoshitake S, Ijiri S et al. Ginkgo biloba leaf extract (EGb 761H) and its specific acylated flavonol constituents increase dopamine and acetylcholine levels in the rat medial prefrontal cortex: possible implications for the cognitive enhancing properties of EGb 761H. Int Psychogeriatr 2012; 1 (Suppl. 24): S25–34.
10. Арушанян Э.Б., Бейер Э.В. Ноотропные свойства препаратов гинкго билоба. Эксперим. и клин. фармакология. 2008; 71 (4): 57–63.
11. Williams B, Watanabe CM, Schultz PG et al. Agerelated effects of Ginkgo biloba extract on synaptic plasticity and excitability. Neurobiol Aging 2004; 25 (7): 955–62.
12. Yoshitake T, Yoshitake S, Kehr J. The Ginkgo biloba extract EGb 761H and its main constituent flavonoids and ginkgolides increase extracellular dopamine levels in the rat prefrontal cortex. Br J Pharmacol 2010; 159: 659–68.
13. Wu Y, Wu Z, Butko P et al. Amyloid-binduced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761H and ginkgolides in transgenic Caenorhabditis elegans. J Neurosci 2006; 26: 13102–13.
14. Luo Y, Smith JV, Paramasivam V et al. Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci USA 2002; 99 (19): 12197–202.
15. Tchantchou F, Xu Y, Wu Y et al. EGb 761H enhances adult hippocampal neurogenesis and phosphorylation of CREB in transgenic mouse model of Alzheimer’s disease. FASEB J 2007; 21: 2400–8.
16. Költringer P, Langsteger W, Ober O. Dose-dependent hemorheological effects and microcirculatory modifications following intravenous administration of Ginkgo biloba special extract EGb 761. Clin Hemorheol 1995; 15: 649–56.
17. Koch E. Inhibition of platelet activating factor (PAF)-induced aggregation of human thrombocytes by ginkgolides: considerations on possible bleeding complications after oral intake of Ginkgo biloba extracts. Phytomed 2005; 12: 10–6.
18. Ahlemeyer B, Krieglstein J. Neuroprotective effects of Ginkgo biloba extract. Cell Mol Life Sci 2003; 60 (9): 1779–92.
19. Weinmann S, Roll S et al. Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. J BMC Geriatr 2010; 10: 14.
20. Amieva H, Meillon C et al. Ginkgo biloba Extract and long-term cognitive decline: a 20-year follow-up population-based study. Ploss One 2013; 8 (1): е52755.
21. Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment in dementia. Dement geriatr Cogn Disord 2000; 11: 230–7.
22. Matcau L. Clinical trial with Bilobil in patients with mild and moderate cognitive impairment. Krka. Data on File 2003.
23. Захаров В.В. Принципы ведения пациентов с когнитивными нарушениями без деменции. РМЖ. 2008; 16 (12): 1645–9.
24. Яхно Н.Н., Захаров В.В., Локшина А.Б. и др. Танакан (EGb 761) в терапии умеренных когнитивных нарушений (мультицентровое исследование). Журн. неврологии и психиатрии. 2006; 12: 41–6.
25. Yancheva S, Ihl R, Nikolova R et al. Ginkgo biloba extract EGb 761R, donepezil or both combined in the treatment of Alzheimer's disease with neuropsychiatric features: A randomised, double-blind, exploratory trial. Aging Ment Health 2008; 13: 183–90.
26. Hoerr R. Treatment effects of EGb 761 and cholinesterase inhibitors – why available studies do not demonstrate superiority of the latter. Phytomed 2005; 12: 598–600.
27. Mazza M, Capuano A et al. Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer’s dementia in a randomized placebo-controlled double-blind study. Eur J Neurol 2006; 13: 981–5.
28. Hofferberth B. Arzneimittelforschung 1989; 39: 918.
29. Itil TM, Eralp E et al. Central nervous System effects of Ginkgo biloba, a plant extract. Am J Ther 1996; 3: 63–73.
30. Hann J, Hoerr R. Delay in progression of dependency and need of care of dementia patients treated with Ginkgo biloba Special Extract EG 761. Wien Med Wochenschr 2004; 154: 21–2.
31. Ihl R, Kretschmar C et al. About evalution of nootropics for the practice. Nervenarzt 1997; 68: 853–61.
32. Яхно Н.Н., Захаров В.В., Страчунская Е.Я. и др. Лечение недементных когнитивных нарушений у пациентов с артериальной гипертензией и церебральным атеросклерозом (По данным российского мультицентрового исследования «ФУЭТЕ»). Лекарственные препараты в неврологии. 2012; с. 49–55.
33. Andrieu S, Gillette S, Amouyal K et al. Association of Alzheimer’s disease onset with ginkgo biloba and other symptomatic cognitive treatments in a population of women aged 75 years and older from the EPIDOS study. J Gerontol A Biol Sci Med Sci 2003; 58: 372–7.
34. DeKosky ST, Williamson JD, Fitzpatrick AL et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 2008; 300 (19): 2253–62.
35. Vellas B, Coley N, Ousset PJ et al. Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer’s disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol 2012; 11 (10): 851–9.
36. Leoutsakos JM, Muthen BO, Breitner JC, Lyketsos CG. Effects of nonsteroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer’s Disease Anti-inflammatory Prevention Trial. Int J Geriatr Psych 2012; 27: 364–74.
37. Raschetti R, Albanese E, Vanacore N, Maggini M. Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med 2007; 4: е338.
38. Марута Н.А., Явдак И.А. Применение Билобила форте в лечении пациентов с дисциркуляторной энцефалопатией (аспекты эффективности и безопасности). Междунар. неврол. журн. 2009; 4 (26).
39. Левин О.С. Подходы к диагностике и лечению когнитивных нарушений при дисциркуляторной энцефалопатии. Трудный пациент. 2008; 11: 14–20.
40. Бугрова С.Г. Эффективность Билобила форте у больных с хронической ишемией мозга I стадии. РМЖ. 2009; 17 (4).
41. Шахпаронова Н.В., Кадыков А.С. Место препарата Билобил в комплексной терапии сосудистых заболеваний головного мозга. Лiки Украiни. 2010; 9: 54–6.
42. Meyer B. Etude multucentrique des accouphenes. Ann Otolaryngol 1986; 103: 185–8.
43. Morgenstern C, Biermann E. The efficacy of Ginkgo biloba Special Extract EG 761 in patients with tinnitus. Int J Clin Farmacol Ther 2002; 40: 188–97.
44. Kennedy DO, Scholey AB et al. The dose-dependent cognitive effects of acute administration of Ginkgo biloba to healthy young volunteers. Psychopharmacol 2000; 151: 416–23.
45. Wolf HR. Does Ginkgo biloba Special Extract EG 761 provide additional effects on coagulation and bleeding when added to acetylsalicylic 500 mg daily? Drugs R D 2006; 7 (3): 163–72.
46. Herrschaft H, Nacu A, Likhachev S et al. Ginkgo biloba extract EGb 761 (R) in dementia with neuropsychiatric features: A randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg. J Psychiatr Res 2012; 46: 716–23.
47. Hofferberth B. Munch Med Wochnschr 1991; 133: 30.
48. Janssen IM, Sturtz S, Skipka G et al. Ginkgo biloba in Alzheimer’s disease: a systematic review. Wien Med Wochenschr 2011; 160: 539–46.
49. Давыдова Т.А., Густов А.В. и др. Применение танакана в комплексном лечении вестибуло-атаксического синдрома у больных с хронической ишемией головного мозга. Журн. неврологии и психиатрии. 2011; 4: 85–6.
50. Яхно Н.Н., Суслина З.А., Грибачева И.А. и др. Влияние препарата Билобил форте на умеренные когнитивные нарушения у пациентов с дисциркуляторной энцефалопатией 1–2 стадии. Клинико-нейропсихологическое исследование. РМЖ. 2007.
2. Eckert A, Keil U et al. Effects of Ginkgo biloba extract on mitochondrial function and oxidative stress. Pharmacopsych 2003; 36 (1): S15–S23.
3. Mairs I, Marocci L et al. Peroxyl radical scavenging activity of Ginkgo biloba Extract EG 761. Biochem Pharmacol 1995; 49: 1649–55.
4. Noda Y, Anzai K et al. Hydroxyl and superoxide anion radical scavenging activities of natural source antioxidants using the computerized JES-FR30 ESR spectrometer system. Biochem Mol Biol Int 1997; 42: 35–44.
5. Bridi R, Crossetti FP et al. The antioxidant activity of extract Ginkgo biloba EGb761 in rats. Phytother Res 2001; 15: 449–51.
6. Abdel-Kader R, Hauptmann S, Keil U et al. Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761H). Pharmacol Res 2007; 56: 493–502.
7. Sastre J, Lloret A et al. Ginkgo biloba extract EGb 761 protects against mitochondrial aging in rat brain and in the liver. Cell Mol Biol 2002; 48: 685–92.
8. Auguet M, DeFeudis FV, Clostre F, Deghenghi R. Effects of an extract of Ginkgo biloba on rabbit isolated aorta. Gen Pharmacol 1982; 13 (3): 225–30.
9. Kehr J, Yoshitake S, Ijiri S et al. Ginkgo biloba leaf extract (EGb 761H) and its specific acylated flavonol constituents increase dopamine and acetylcholine levels in the rat medial prefrontal cortex: possible implications for the cognitive enhancing properties of EGb 761H. Int Psychogeriatr 2012; 1 (Suppl. 24): S25–34.
10. Арушанян Э.Б., Бейер Э.В. Ноотропные свойства препаратов гинкго билоба. Эксперим. и клин. фармакология. 2008; 71 (4): 57–63.
11. Williams B, Watanabe CM, Schultz PG et al. Agerelated effects of Ginkgo biloba extract on synaptic plasticity and excitability. Neurobiol Aging 2004; 25 (7): 955–62.
12. Yoshitake T, Yoshitake S, Kehr J. The Ginkgo biloba extract EGb 761H and its main constituent flavonoids and ginkgolides increase extracellular dopamine levels in the rat prefrontal cortex. Br J Pharmacol 2010; 159: 659–68.
13. Wu Y, Wu Z, Butko P et al. Amyloid-binduced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761H and ginkgolides in transgenic Caenorhabditis elegans. J Neurosci 2006; 26: 13102–13.
14. Luo Y, Smith JV, Paramasivam V et al. Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci USA 2002; 99 (19): 12197–202.
15. Tchantchou F, Xu Y, Wu Y et al. EGb 761H enhances adult hippocampal neurogenesis and phosphorylation of CREB in transgenic mouse model of Alzheimer’s disease. FASEB J 2007; 21: 2400–8.
16. Költringer P, Langsteger W, Ober O. Dose-dependent hemorheological effects and microcirculatory modifications following intravenous administration of Ginkgo biloba special extract EGb 761. Clin Hemorheol 1995; 15: 649–56.
17. Koch E. Inhibition of platelet activating factor (PAF)-induced aggregation of human thrombocytes by ginkgolides: considerations on possible bleeding complications after oral intake of Ginkgo biloba extracts. Phytomed 2005; 12: 10–6.
18. Ahlemeyer B, Krieglstein J. Neuroprotective effects of Ginkgo biloba extract. Cell Mol Life Sci 2003; 60 (9): 1779–92.
19. Weinmann S, Roll S et al. Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. J BMC Geriatr 2010; 10: 14.
20. Amieva H, Meillon C et al. Ginkgo biloba Extract and long-term cognitive decline: a 20-year follow-up population-based study. Ploss One 2013; 8 (1): е52755.
21. Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment in dementia. Dement geriatr Cogn Disord 2000; 11: 230–7.
22. Matcau L. Clinical trial with Bilobil in patients with mild and moderate cognitive impairment. Krka. Data on File 2003.
23. Захаров В.В. Принципы ведения пациентов с когнитивными нарушениями без деменции. РМЖ. 2008; 16 (12): 1645–9.
24. Яхно Н.Н., Захаров В.В., Локшина А.Б. и др. Танакан (EGb 761) в терапии умеренных когнитивных нарушений (мультицентровое исследование). Журн. неврологии и психиатрии. 2006; 12: 41–6.
25. Yancheva S, Ihl R, Nikolova R et al. Ginkgo biloba extract EGb 761R, donepezil or both combined in the treatment of Alzheimer's disease with neuropsychiatric features: A randomised, double-blind, exploratory trial. Aging Ment Health 2008; 13: 183–90.
26. Hoerr R. Treatment effects of EGb 761 and cholinesterase inhibitors – why available studies do not demonstrate superiority of the latter. Phytomed 2005; 12: 598–600.
27. Mazza M, Capuano A et al. Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer’s dementia in a randomized placebo-controlled double-blind study. Eur J Neurol 2006; 13: 981–5.
28. Hofferberth B. Arzneimittelforschung 1989; 39: 918.
29. Itil TM, Eralp E et al. Central nervous System effects of Ginkgo biloba, a plant extract. Am J Ther 1996; 3: 63–73.
30. Hann J, Hoerr R. Delay in progression of dependency and need of care of dementia patients treated with Ginkgo biloba Special Extract EG 761. Wien Med Wochenschr 2004; 154: 21–2.
31. Ihl R, Kretschmar C et al. About evalution of nootropics for the practice. Nervenarzt 1997; 68: 853–61.
32. Яхно Н.Н., Захаров В.В., Страчунская Е.Я. и др. Лечение недементных когнитивных нарушений у пациентов с артериальной гипертензией и церебральным атеросклерозом (По данным российского мультицентрового исследования «ФУЭТЕ»). Лекарственные препараты в неврологии. 2012; с. 49–55.
33. Andrieu S, Gillette S, Amouyal K et al. Association of Alzheimer’s disease onset with ginkgo biloba and other symptomatic cognitive treatments in a population of women aged 75 years and older from the EPIDOS study. J Gerontol A Biol Sci Med Sci 2003; 58: 372–7.
34. DeKosky ST, Williamson JD, Fitzpatrick AL et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 2008; 300 (19): 2253–62.
35. Vellas B, Coley N, Ousset PJ et al. Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer’s disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol 2012; 11 (10): 851–9.
36. Leoutsakos JM, Muthen BO, Breitner JC, Lyketsos CG. Effects of nonsteroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer’s Disease Anti-inflammatory Prevention Trial. Int J Geriatr Psych 2012; 27: 364–74.
37. Raschetti R, Albanese E, Vanacore N, Maggini M. Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med 2007; 4: е338.
38. Марута Н.А., Явдак И.А. Применение Билобила форте в лечении пациентов с дисциркуляторной энцефалопатией (аспекты эффективности и безопасности). Междунар. неврол. журн. 2009; 4 (26).
39. Левин О.С. Подходы к диагностике и лечению когнитивных нарушений при дисциркуляторной энцефалопатии. Трудный пациент. 2008; 11: 14–20.
40. Бугрова С.Г. Эффективность Билобила форте у больных с хронической ишемией мозга I стадии. РМЖ. 2009; 17 (4).
41. Шахпаронова Н.В., Кадыков А.С. Место препарата Билобил в комплексной терапии сосудистых заболеваний головного мозга. Лiки Украiни. 2010; 9: 54–6.
42. Meyer B. Etude multucentrique des accouphenes. Ann Otolaryngol 1986; 103: 185–8.
43. Morgenstern C, Biermann E. The efficacy of Ginkgo biloba Special Extract EG 761 in patients with tinnitus. Int J Clin Farmacol Ther 2002; 40: 188–97.
44. Kennedy DO, Scholey AB et al. The dose-dependent cognitive effects of acute administration of Ginkgo biloba to healthy young volunteers. Psychopharmacol 2000; 151: 416–23.
45. Wolf HR. Does Ginkgo biloba Special Extract EG 761 provide additional effects on coagulation and bleeding when added to acetylsalicylic 500 mg daily? Drugs R D 2006; 7 (3): 163–72.
46. Herrschaft H, Nacu A, Likhachev S et al. Ginkgo biloba extract EGb 761 (R) in dementia with neuropsychiatric features: A randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg. J Psychiatr Res 2012; 46: 716–23.
47. Hofferberth B. Munch Med Wochnschr 1991; 133: 30.
48. Janssen IM, Sturtz S, Skipka G et al. Ginkgo biloba in Alzheimer’s disease: a systematic review. Wien Med Wochenschr 2011; 160: 539–46.
49. Давыдова Т.А., Густов А.В. и др. Применение танакана в комплексном лечении вестибуло-атаксического синдрома у больных с хронической ишемией головного мозга. Журн. неврологии и психиатрии. 2011; 4: 85–6.
50. Яхно Н.Н., Суслина З.А., Грибачева И.А. и др. Влияние препарата Билобил форте на умеренные когнитивные нарушения у пациентов с дисциркуляторной энцефалопатией 1–2 стадии. Клинико-нейропсихологическое исследование. РМЖ. 2007.
Авторы
Е.А.Катунина
ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздрава России, Москва
ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздрава России, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.